Separate prescribing authority from a successful remote visit
Rule 38 restricts controlled-substance prescriptions unless its in-person or specified relationship conditions are met. Those include defined consultation, referral, coverage or ongoing-relationship situations. Review the actual facts instead of treating any completed video call as sufficient.
For controlled medications, the DEA and HHS fourth temporary extension of telemedicine prescribing flexibilities runs through December 31, 2026, subject to its conditions. It does not guarantee a prescription or replace state requirements, and any reliance on it beyond that date needs a fresh review. Arkansas requirements remain relevant. Have the medical lead approve the proposed medication scope and review it before the federal period ends. A business plan should not depend on a permanent continuation that has not been established.
Keep this decision separate from patient payment. The fee buys the disclosed service, not a guaranteed drug. If the evaluation leads to outside care or no prescription, the explanation should remain consistent with the original offer. Staff need approved language for that outcome and a route for clinical questions.